Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | HNF4A | P41235 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28391093 | 0.82 | MAPT (0.44) | ALDH1A1MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL27606300 | 0.82 | HSD17B1 (0.48) | ALDH1A1 | |
| SCHEMBL27588556 | 0.82 | MAOA (0.47) | MAOAMEN1MCL1 | |
| SCHEMBL27606371 | 0.81 | ESR1 (0.42) | MEN1KMT2AALOX5 | |
| SCHEMBL27606396 | 0.81 | CYP3A4 (0.41) | ALDH1A1TAAR1MEN1KMT2ANPC1 | |
| SCHEMBL27606577 | 0.81 | ALOX5 (0.38) | ALDH1A1TAAR1KMT2AALOX5AOC3 | |
| SCHEMBL27606428 | 0.79 | CYP1A2 (0.46) | ALDH1A1USP2LMNAMAPK1 | |
| SCHEMBL27606352 | 0.78 | ABL1 (0.43) | ALDH1A1MAOAMEN1KMT2ANPC1 | |
| SCHEMBL27588572 | 0.78 | HTR7 (0.46) | ALDH1A1TAAR1AOC3 | |
| SCHEMBL27606433 | 0.78 | AOC3 (0.38) | TAAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| WO-2021006267-A1 | SALT OF PYRAZOLE DERIVATIVE AND PREPARATION OF PYRAZOLE DERIVATIVE | グリーン・テック株式会社 | 2021-01-14 | — | — | WO | disclosed |
| CN-112105611-A | Pharmaceutical combination comprising a Histone Deacetylase (HDAC) inhibitor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer | 4SC股份公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-112055589-A | Combination comprising an HDAC inhibitor, a LAG-3 inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor for the treatment of cancer | 4SC股份公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-112004535-A | Combination comprising an HDAC inhibitor and a CD137 agonist for cancer therapy | 4SC股份公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2020235582-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR MOTOR NEURON DISEASE | グリーン・テック株式会社 (JP) | 2020-11-26 | — | — | WO | disclosed |
| CN-111432884-A | Combination of HDAC inhibitors with immune checkpoint modulators for cancer therapy | 4SC股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1066268-A1 | 5-SUBSTITUTED PYRIMIDINE-2-YLOXY CARBOXYLIC ACID DERIVATIVES, THE PRODUCTION OF THE SAME AND THEIR UTILIZATION AS ENDOTHELIN ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999042453-A1 | 5-SUBSTITUTED PYRIMIDINE-2-YLOXY CARBOXYLIC ACID DERIVATIVES, THE PRODUCTION OF THE SAME AND THEIR UTILIZATION AS ENDOTHELIN ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | ALDH1A1 675/4885TAAR1 935/4885MAOA 909/4885 |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | ALDH1A1 4394/4885TAAR1 2761/4885MAOA 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.